Why DexCom, Inc. (DXCM) Stock Fell 6.4% on Oct 21, 2026
What happened
DexCom fell 6.62% to $80.06 as of 140 minutes into the session, despite recent FDA clearance for its glucose monitoring system and management statements that no deal is on the table, per Barron's reporting. Volume at 2.36M shares runs 1.96x the historical average for this time of day, suggesting active selling pressure despite the positive regulatory news.
DexCom earnings release scheduled for October 29, 2026 (consensus EPS estimate $0.68); monitor for any guidance revision or commentary on glucose monitoring adoption and competitive dynamics.
Frequently asked questions
Why did DexCom, Inc. (DXCM) stock fall on Oct 21, 2026?
DexCom fell 6.62% to $80.06 as of 140 minutes into the session, despite recent FDA clearance for its glucose monitoring system and management statements that no deal is on the table, per Barron's reporting. Volume at 2.36M shares runs 1.96x the historical average for this time of day, suggesting active selling pressure despite the positive regulatory news.
How much did DXCM stock fall on Oct 21, 2026?
DXCM fell 6.4% during the Oct 21, 2026 trading session.